NRSN Stock Analysis: Buy, Sell, or Hold?
NRSN - NeuroSense Therapeutics Ltd. Ordinary Shares
$3.94
-0.11 (-2.84%)
▼
5d:
-43.38%
30d:
+857.89%
90d:
+465.37%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Jun 30, 2026
0d
Get Alerted When NRSN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NRSN is down 43.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NRSN is down 43.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NRSN is currently trading at $3.94, which is considered fair relative to its 30-day fair value range of $0.48 to $6.42.
Technical Outlook: Technically, NRSN is in a uptrend. The price is currently testing key support at $3.82. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NRSN scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $97.33 (+2373.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NRSN is in a uptrend. The price is currently testing key support at $3.82. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NRSN scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $97.33 (+2373.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.48 -
$6.42
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 2373.5% below Wall St target ($97.33)
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.48 -
$6.42
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.82
Resistance Level
$7.41
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.33
Wall Street Target
$97.33
(+2373.5%)
Share & Embed Analysis
Last updated: October 03, 2026 1:04 PM ET
Data refreshes hourly during market hours. Next update: 2:04 PM
Data refreshes hourly during market hours. Next update: 2:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NRSN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$851 | 48 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 67 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 62 BUY |
